此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Chromium Weight Reduction on Adult Asthma Control (ECWAC)

2026年7月11日 更新者：Amani Mohamed、Cairo University

This phase IV randomized controlled trial is designed to evaluate the effects of chromium picolinate supplementation in obese adults with stable asthma. A total of 60 participants will be recruited from Ain Shams University Hospitals and randomly assigned to receive either 400 mcg of chromium picolinate daily or a matching placebo for 12 weeks, in addition to standard asthma therapy.

The study aims to explore the interaction between metabolic dysfunction and asthma, as obesity-related asthma is often associated with systemic inflammation, insulin resistance, and dyslipidemia. These factors may contribute to poorer asthma control and impaired pulmonary function, and therefore represent potential targets for adjunctive therapeutic interventions such as chromium supplementation.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

Study Design and Setting This study is a phase IV randomized controlled clinical trial (RCT) involving 60 adult patients diagnosed with asthma. Participants will be recruited from the outpatient clinic and pulmonary function unit of the Chest Department at Ain Shams University Hospitals.

Study Type: Phase IV randomized controlled clinical trial (RCT) Study Setting: Outpatient clinic and pulmonary function unit, Chest Department, Ain Shams University Hospitals Study Population: Adult patients with asthma, obesity, and diabetes mellitus

Sampling and Randomization Participants will be randomly assigned to study groups using computer-generated randomization sequences. Allocation concealment will be ensured through the use of sealed, opaque envelopes.

Ethical Considerations

The study protocol will be explained clearly to all eligible participants prior to enrollment.

The study will commence only after obtaining approval from the Ethical Committee of the Faculty of Medicine, Ain Shams University.

Written informed consent will be obtained from all participants prior to inclusion.

Participant safety will be prioritized, and all efforts will be made to minimize potential risks.

Confidentiality and anonymity of participant data will be strictly maintained. All participants will have an equal chance of being assigned to either study group.

No deceptive practices will be used during the study. Participants will have the right to withdraw from the study at any time without any consequences.

Study Procedures

All eligible participants will undergo the following assessments:

Demographic Data Collection: Age, sex, smoking status, and body mass index (BMI) Clinical Assessment: Detailed medical history including environmental exposures, potential risk factors, comorbidities, and duration of disease

Concomitant Care All participants will continue receiving standard asthma therapy throughout the study period.

Participants will be instructed to maintain a consistent intake of chromium-rich foods during the study to avoid dietary confounding.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age: 18-65 years
  • Confirmed asthma diagnosis according to GINA criteria (7)
  • Asthma stable for at least 4 weeks (no acute exacerbation)
  • BMI of 30 kg/m² (obese category)
  • Stable inhaled corticosteroid + LABA regimen in the last 4 weeks
  • The patient is compliant on his asthma medication
  • Willing and able to provide informed consent
  • willing to continue in the study, follow investigator instructions

Exclusion Criteria:

  • - Recent asthma exacerbation (within the last 4 weeks)
  • Any change in asthma medications within 4 weeks
  • renal or hepatic disease
  • Use of lipid-lowering drugs or supplements in the past 3 months
  • Use of Vitamin C, prostaglandin inhibitors, such as aspirin, oxalate, and antacids
  • Current pregnancy or lactation
  • Known allergy to chromium or adverse reaction to supplementation
  • Participation in another interventional study in the past month
  • History of heavy metal toxicity or chromium sensitivity
  • Being on any weight control diet
  • Being on a supplement containing chromium

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
无干预：Standard of Care

All participants continue standard asthma therapy and management

- Study participants will be instructed to keep their dietary consumption of chromium rich foods constant all over the study period.
实验性的：Chromium Picolinate

Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium.

Taken once daily for 12 weeks.
膳食补充剂：Chromium picolinate

Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium.

Taken once daily for 12 weeks.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change in asthma control
大体时间：from baseline to 12 weeks
Change in Asthma Control Test (ACT) Score (points; range 5-25)
from baseline to 12 weeks
Spirometry
大体时间：from baseline to 12 weeks
Forced Expiratory Volume in 1 second (FEV₁) - L or % predicted
from baseline to 12 weeks
Frequency of rescue medication use
大体时间：from baseline to 12 weeks
Frequency of Asthma Inhalers used
from baseline to 12 weeks
Asthma exacerbation frequency
大体时间：from baseline to 12 weeks
Asthma exacerbation frequency
from baseline to 12 weeks

次要结果测量

结果测量
措施说明
大体时间
Lipid Profile
大体时间：From baseline to 12 weeks
Change in fasting total, HDL, LDL Cholesterol in addition to the triglycerides
From baseline to 12 weeks
Anthropometric Measurements
大体时间：From baseline to 12 weeks
Change in Body Mass Index (BMI) Unit of Measure: kg/m²
From baseline to 12 weeks
Incidence of Treatment-Emergent Adverse Events
大体时间：Monthly from baseline to 3 months
The outcome measure will assess the frequency of adverse effects occurring during the study period.
Monthly from baseline to 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Cairo University

合作者

Ain Shams University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月20日

初级完成 (估计的)

2027年8月20日

研究完成 (估计的)

2027年8月20日

研究注册日期

首次提交

2026年4月8日

首先提交符合 QC 标准的

2026年7月11日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年7月14日

上次提交的符合 QC 标准的更新

2026年7月11日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • FMASU R62/2026 (注册表标识符：Ain Shams Faculty of Medicine Institutional Review Board)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

De-identified individual participant data underlying the results reported in publications arising from this study, including demographic, clinical, and outcome data, will be made available.

IPD 共享时间框架

De-identified individual participant data will be made available beginning 6 months after publication of the primary study results and will be available indefinitely.

IPD 共享访问标准

Data will be available upon reasonable request to the principal investigator. Requests will be reviewed for scientific merit and compliance with applicable ethical and regulatory requirements. Data-sharing agreements may be required before access is granted.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅